Providing affordable access to new treatment for leukaemia and lymphoma
Leukaemia and lymphoma patients in Forde will benefit from affordable access to a new medicine, with the Turnbull Government subsidising the drug. Ibrutinib (sold as Imbruvica®) would normally cost $187,390 on average per course of treatment, putting it beyond the reach of most patients. This $466 million listing on the Pharmaceutical Benefits Scheme (PBS) will…